Search

TAS-102

TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer.

Piclamilast

Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

Tuxobertinib

Tuxobertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Tuxobertinib is a epidermal growth factor receptor (EGFR) inhibitor. … Tuxobertinib has a monoisotopic molecular weight of 560.19 Da.

Acetylcysteine zidrimer

L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle. … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

Carotuximab

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

ATG-101

, while delivering enhanced anti-tumor activity, with an improved safety profile. … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

VPM4001

VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.

L-cysteic acid

L-cysteic acid is a beta-sulfoalanine. It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate.